Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease

benzinga.com/news/health-care/25/10/48281451/sanofis-rezurock-approval-stumbles-in-eu-for-chronic-graft-vs-host-disease

On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ:SNY) Rezurock (belumosudil).
The French drug maker was seeking approval for Rezurock for the third-line treatment of adults and pediatric…

This story appeared on benzinga.com, 2025-10-17 17:03:37.
The Entire Business World on a Single Page. Free to Use →